January 24, 2006 |
Botox maker Allergan Inc. said it was extending its $3.2-billion offer to buy breast implant maker Inamed Corp. because it had yet to get antitrust clearance from regulators. The offer is now set to expire at 8 p.m. on Feb. 7; it had been set to expire today. Irvine-based Allergan and Santa Barbara-based Inamed said they were working with the Federal Trade Commission to complete the sale of Inamed's license for Reloxin, a botulism toxin product.
August 2, 2007
Allergan Inc. posted stronger-than-expected quarterly earnings Wednesday on higher sales of prescription drugs, medical devices and its Botox anti-wrinkle product. Second-quarter profit rose to $138 million, or 45 cents a share, from $74 million, or 24 cents, a year earlier. Excluding special items, the Irvine-based company earned 54 cents a share, topping the average forecast by analysts of 3 cents, according to Reuters Estimates.